Eli Lilly commits to a long-term global expansion plan, aiming to provide equitable access to its innovative diabetes and obesity portfolio in developing nations by 2040.
Lilly announced a commitment to expand access to diabetes and obesity medicines in LMICs, which may have long-term reputational and market expansion implications but no immediate financial impact.
Eli Lilly has announced a strategic initiative to expand the availability of its diabetes and obesity treatments to low- and middle-income countries. The company aims to achieve parity in access between resource-limited settings and high-income nations by 2040.
Lilly aims to ensure that people in low- and middle-income countries have the same access to its diabetes and obesity medicines as those in high-income countries by the year 2040.